Glanzmann's thrombasthenia diagnostic study of choice
|
Glanzmann's thrombasthenia |
|
Differentiating Glanzmann's thrombasthenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glanzmann's thrombasthenia diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Glanzmann's thrombasthenia diagnostic study of choice |
|
FDA on Glanzmann's thrombasthenia diagnostic study of choice |
|
CDC on Glanzmann's thrombasthenia diagnostic study of choice |
|
Glanzmann's thrombasthenia diagnostic study of choice in the news |
|
Blogs on Glanzmann's thrombasthenia diagnostic study of choice |
|
Risk calculators and risk factors for Glanzmann's thrombasthenia diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[3], Niyousha Danesh, MD-MPH
Overview
There is no single study of choice for the diagnosis of Glanzmann's thrombasthenia, but it can be diagnosed based on platelet aggregation assays which constitute a panel of assays measuring platelet aggregation and activation in vitro using agonists like ADP, arachidonic acid, collagen, epinephrine, thrombin, and ristocetin.The diagnosis of Glanzmann thrombasthenia is confirmed through monoclonal antibody testing and flow cytometry.
Diagnostic study of choice
There is no single study of choice for the diagnosis of Glanzmann's thrombasthenia, but it can be diagnosed based on platelet aggregation assays which constitute a panel of assays measuring platelet aggregation and activation in vitro. Agonists that are used in this laboratory test include ADP, arachidonic acid, collagen, epinephrine, thrombin, and ristocetin. The diagnosis of Glanzmann thrombasthenia is confirmed through monoclonal antibody testing and flow cytometry [1][2][3][4][5]
References
- ↑ Quiroga T, Goycoolea M, Matus V, Zúñiga P, Martínez C, Garrido M, Aranda E, Leighton F, Panes O, Pereira J, Mezzano D (December 2009). "Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays". Br. J. Haematol. 147 (5): 729–36. doi:10.1111/j.1365-2141.2009.07890.x. PMID 19775303.
- ↑ Jennings I, Woods TA, Kitchen S, Walker ID (August 2008). "Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006". J. Clin. Pathol. 61 (8): 950–4. doi:10.1136/jcp.2008.057174. PMID 18663056.
- ↑ Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD (June 2009). "Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH". J. Thromb. Haemost. 7 (6): 1029. doi:10.1111/j.1538-7836.2009.03458.x. PMID 19422455.
- ↑ Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM (April 2009). "Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments". J. Thromb. Haemost. 7 (4): 676–84. doi:10.1111/j.1538-7836.2009.03273.x. PMID 19143930.
- ↑ BORN GV (June 1962). "Aggregation of blood platelets by adenosine diphosphate and its reversal". Nature. 194: 927–9. PMID 13871375.